Exenatide increases CTRP3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis
Yazarlar (5)
Meliha Koldemir Gündüz
Kutahya Health Sciences University, Türkiye
Güllü Kaymak
Kutahya Health Sciences University, Türkiye
Dr. Öğr. Üyesi Ertan KANBUR
Uludag University, Türkiye
Derya Berikten
Kütahya Sağlık Bilimleri Üniversitesi, Türkiye
Harun Şener
Kütahya Sağlık Bilimleri Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | TOXICOLOGY IN VITRO (Q2) | ||
| Dergi ISSN | 0887-2333 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | Türkçe | Basım Tarihi | 12-2022 |
| Cilt / Sayı / Sayfa | 85 / 0 / – | DOI | 10.1016/j.tiv.2022.105479 |
| Makale Linki | http://dx.doi.org/10.1016/j.tiv.2022.105479 | ||
| Özet |
| Considering the rapidly increasing prevalence of obesity worldwide, the number of weight control drugs is very few. Incretin-based therapies are currently being developed to achieve weight control, and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) are used in incretin-based therapies. This study aimed to investigate the cytotoxicity of exenatide, a GLP-1A, on 3T3-L1 adipocytes and the effect of exenatide on the expression of adipogenesis-related genes, insulin and glucose levels, and apoptosis. Cytotoxic activity of exenatide on 3T3-L1 adipocytes was determined by MTT method. Gene expression levels were determined by qPCR. Apoptosis studies were performed on the Muse Cell Analyzer. C1q/TNF-related protein-3 (CTRP3) expression levels were found to be higher in exenatide treated adipocyte cells than in control cells (p < 0.001). Adipocyte cells treated with exenatide were found to have lower PPAR-gamma gene expression levels when compared to control adipocyte cells (p < 0.001). Intracellular insulin (p < 0.001) and glucose levels were higher in 3T3-L1 adipocytes treated with exenatide compared to control adipocyte cells. Total apoptosis increased approximately 1.5 times as a result of exenatide administration. The increase in CTRP3 gene expression, which is thought to be a new biomarker for obesity, and the decrease in PPAR-gamma gene expression indicate that exenatide is a promising new pharmaco-therapeutic agent in the treatment of obesity by regulating the expression of genes related to adipogenesis and lipogenesis and inducing apoptosis. |
| Anahtar Kelimeler |
| Obesity | Adipogenesis | 3T3-L1 cell line | Exenatide | CTRP3 gene |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| WoS | 3 |
| Google Scholar | 4 |